The purpose of this study is to test whether a new drug regimen will reduce the chances of side effects but be just as effective as the usual treatment for HER2-positive, ER-negative and node negative breast cancer.
MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Liquid-Biopsy Monitoring for Patients not yet Eligible for Screening and Enrollment
Oral presentation by Dr Laura Dawson at the ASCO Gastrointestinal Cancer Symposium 2023 of results for the CCTG HE1 phase III study of palliative radiation therapy for symptomatic hepatocellular carcinoma and liver metastases.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)
PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)
Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC
Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma
Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy
Androgen Suppression Combined with Elective Nodal Irradiation and Dose Escalated Prostate Treatment (ASCENDE-SBRT)
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS
STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study
Mark your calendars! Dr Lillian Siu is our guest speaker this year at the Maria Ricci Memorial Lectureship In Oncology taking place at the CCTG Spring Meeting on Saturday April 29, 5:00 pm in the Mountbatten Room at the Chelsea Hotel in Toronto. Dr Siu's lecture is titled "Precision Cancer Medicine Beyond Next Generation Sequencing Gene Panels". This session is RCPSC accredited
About Dr Lillian Siu
The inaugural CCTG Award for Excellence in Clinical Trials Conduct will be presented this year at the Recognition Awards at the Annual Spring Meeting of Participants to an individual who exemplifies excellence in clinical trial operations and/or compliance at their institution.
#CCTG2023 is fast approaching and you are running out of time and if you have not register or requested an invitation please do so now!
Practice changing data presented in endometrial cancer that demonstrates improved progression-free survival outcomes with the addition of Pembrolizumab to chemotherapy for women with advanced or recurrent endometrial cancer.
CCTG is looking for members for our Equity, Diversity, Inclusivity, Indigenization, and Accessibility (EDIIA) Working Groups as part of our EDIIA Action Plan. CCTG strives to create an equitable, diverse, inclusive, accessible, and culturally safe community for our network and for patients.
Canadian Neuroendocrine Tumour Society (CNETS) 2022 Research Grant Award to support Canadian participation in STOPNET international trial. STOPNET is a Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours.